Innate Pharma: the cash position is 131.7 ME without the payment of AstraZeneca











Photo credit © Reuters


(Boursier.com) — The turnover ofInnate Pharma for the first 3 months of 2022 amounted to 2.6 million euros (4.5 ME for the 1st quarter of 2021). For the 3-month period ending March 31, 2022, revenue comes mainly from the accounting spread of payments received under collaboration and license agreements with Astra Zeneca.

As of March 31, 2022, cash, cash equivalents and financial assets of Innate Pharma amounted to €131.7 million. On the same date, the company’s total financial liabilities amounted to €43.8 million. The Company’s cash, cash equivalents and financial assets as of March 31 do not include the $50 million milestone payment receivable from AstraZeneca.

“In the 1st quarter, we continued to advance our portfolio, and more particularly monalizumab, our anti-NKG2A antibody, whose clinical development continues to advance with, in particular, the treatment in April of the first patient in a Phase 3 in locally advanced lung cancer. This triggered a $50 million milestone payment from AstraZeneca and therefore strengthens our cash position and funds our programs through 2024,” said Mondher Mahjoubi. , Chairman of the Management Board of Innate Pharma. “We continue to execute our strategy to make the most of our product portfolio and bring innovative treatments to cancer patients, with new clinical data for lacutamab in the second half and the advancement of our ANKET platform”.


©2022 Boursier.com






Source link -87